Shares of Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) have received a consensus recommendation of "Buy" from the seven brokerages that are covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $11.83.
A number of equities research analysts recently weighed in on RZLT shares. Wall Street Zen downgraded shares of Rezolute from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Wedbush reissued an "outperform" rating and set a $12.00 price target on shares of Rezolute in a research note on Wednesday, May 14th. Finally, HC Wainwright reissued a "buy" rating and set a $14.00 price target on shares of Rezolute in a research note on Monday, April 28th.
View Our Latest Analysis on Rezolute
Rezolute Stock Performance
Shares of NASDAQ RZLT traded down $0.09 during trading on Wednesday, reaching $5.20. The company had a trading volume of 141,400 shares, compared to its average volume of 658,943. Rezolute has a 52 week low of $2.22 and a 52 week high of $6.19. The stock has a market cap of $444.27 million, a PE ratio of -4.51 and a beta of 1.03. The business's 50 day moving average price is $4.16 and its 200-day moving average price is $4.10.
Rezolute (NASDAQ:RZLT - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). Equities analysts anticipate that Rezolute will post -0.93 earnings per share for the current year.
Insider Buying and Selling
In other news, Director Young-Jin Kim bought 1,230,769 shares of the stock in a transaction on Friday, June 13th. The stock was purchased at an average price of $3.25 per share, with a total value of $3,999,999.25. Following the completion of the purchase, the director owned 8,423,386 shares of the company's stock, valued at approximately $27,376,004.50. This trade represents a 17.11% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have purchased a total of 1,241,345 shares of company stock valued at $4,041,196 over the last ninety days. 18.39% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Rezolute
Large investors have recently bought and sold shares of the company. Man Group plc bought a new stake in Rezolute in the fourth quarter valued at approximately $425,000. Geode Capital Management LLC boosted its holdings in shares of Rezolute by 5.2% in the fourth quarter. Geode Capital Management LLC now owns 517,014 shares of the company's stock valued at $2,535,000 after buying an additional 25,413 shares during the period. Ameriprise Financial Inc. acquired a new position in shares of Rezolute in the fourth quarter valued at approximately $342,000. Barclays PLC acquired a new position in shares of Rezolute in the fourth quarter valued at approximately $314,000. Finally, Nantahala Capital Management LLC boosted its holdings in shares of Rezolute by 10.9% in the fourth quarter. Nantahala Capital Management LLC now owns 2,857,982 shares of the company's stock valued at $14,004,000 after buying an additional 280,861 shares during the period. Institutional investors own 82.97% of the company's stock.
Rezolute Company Profile
(
Get Free ReportRezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
Featured Articles

Before you consider Rezolute, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rezolute wasn't on the list.
While Rezolute currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.